Systemic Effects of Topically Applied Sunscreen Ingredients

Clinical Guide to Sunscreens and Photoprotection

Volumn , Issue , 2008, Pages 139-154

  Nash, J Frank ^a  

^a PROCTER AND GAMBLE COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80053534501     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.3109/9781420080858-13     Document Type: Chapter

References (60)

1. Tanner PR. Sunscreen product formulation. Dermatol Clin 2006; 24(1): 53-62.
2. Jiang R, Roberts MS, Collins DM, et al. Absorption of sunscreens across human skin: an evaluation of commercial products for children and adults. Br J Clin Pharmacol 1999; 48(4): 635-637.
3. Hayden CGJ, Cross SE, Anderson C, et al. Sunscreen penetration of human skin and related keratinocyte toxicity after topical application. Skin Pharmacol Physiol 2005; 18(4): 170-174.
4. Hayden CG, Roberts MS, Benson HA. Systemic absorption of sunscreen after topical application. Lancet 1997; 350(9081): 863-864.
5. Gustavsson Gonzalez H, Farbrot A, Larkö O. Percutaneous absorption of benzophenone-3, a common component of topical sunscreens. Clin Exp Dermatol 2002; 27(8): 691-694.
6. Janjua NR, Mogensen B, Andersson AM, et al. Systemic absorption of the sunscreens benzophenone-3, octyl-methoxycinnamate, and 3-(4-methyl-benzylidene) camphor after wholebody topical application and reproductive hormone levels in humans. J Invest Dermatol 2004; 123(1): 57-61.
7. Angerer J, Ewers U, Wilhelm M. Human biomonitoring: state of the art. Int J Hyg Environ Health 2007; 210(3-4): 201-228.
8. Calafat AM, Ye X, Silva MJ, et al. Human exposure assessment to environmental chemicals using biomonitoring. Int J Androl 2006; 29(1): 166-171.
9. Risk Assessment in the Federal Government: Managing the Process. Committee on the International Means for Assessment of Risks to Public Health, Commission Life Sciences, NRC 1983.
10. Cosmetic Ingredient Review,. Final report on the safety assessment of benzophenones-1, -3, -4, -5, -9 and -11. J Am Coll Toxicol 1983; 2(5):35-77.
11. Thune P. Contact and photocontact allergy to sunscreens. Photodermatol 1984; 1(1): 5-9.
12. Menz J, Muller SA, Connolly SM. Photopatch testing: a six-year experience. J Am Acad Dermatol 1988; 18(5 pt 1): 1044-1047.
13. Nohynek GJ, Schaefer H. Benefit and risk of organic ultraviolet filters. Regul Toxicol Pharmacol 2001; 33(3): 285-299.
14. Chatelain E, Gabard B, Surber C. Skin penetration and sun protection factor of five UV filters:effect of the vehicle. Skin Pharmacol Appl Skin Physiol 2003; 16(1): 28-35.
15. Geinoz S, Guy RH, Testa B, et al. Quantitative structure-permeation relationships (QSPeRs) to predict skin permeation: a critical evaluation. Pharm Res 2004; 21(1): 83-92.
16. Walters KA, Brain KR, Howes D, et al. Percutaneous penetration of octyl salicylate from representative sunscreen formulations through human skin in vitro. Food Chem Toxicol 1997; 35(12): 1219-1225.
17. Benech-Kieffer F, Wegrich P, Schwarzenbach R, et al. Percutaneous absorption of sunscreens in vitro: interspecies comparison, skin models and reproducibility aspects. Skin Pharmacol Appl Skin Physiol 2000; 13(6): 324-335.
18. Nielsen JB, Nielsen F, Srensen JA. Defense against dermal exposures is only skin deep:significantly increased penetration through slightly damaged skin. Arch Dermatol Res 2007; 299(9): 423-431.
19. Borm PJA, Robbins D, Haubold S, et al. The potential risks of nanomaterials: a review carried out for ECETOC. Particle Fibre Toxicol 2006; 3:11.
20. Stender IM, Andersen JL, Wulf HC. Sun exposure and sunscreen use among sunbathers in Denmark. Acta Derm Venereol 1996; 76(1): 31-33.
21. Stenberg C, Larko O. Sunscreen application and its importance for the sun protection factor. Arch Dermatol 1985; 121(11): 1400-1402.
22. Pruim B, Green A. Photobiological aspects of sunscreen re-application. Australas J Dermatol 1999; 40(1): 14-18.
23. Gasparro FP, Mitchnick M, Nash JF. A review of sunscreen safety and efficacy. Photochem Photobiol 1998; 68(3): 243-256.
24. Nash JF. Human safety and efficacy of ultraviolet filters and sunscreen products. Dermatol Clin 2006; 24(1): 35-51.
25. Nohynek GJ, Lademann J, Ribaud C, et al. Grey goo on the skin? Nanotechnology, cosmetic and sunscreen safety. Crit Rev Toxicol 2007; 37(3): 251-277.
26. Tan MH, Commens CA, Burnett L, et al. A pilot study on the percutaneous absorption of microfine titanium dioxide from sunscreens. Australas J Dermatol 1996; 37(4): 185-187.
27. Dussert A-S, Gooris E, Hemmerle J. Characterization of the mineral content of a physical sunscreen emulsion and its distribution onto human stratum corneum. Int J Cosmet Sci 1997; 19:119-129.
28. Pflucker F, Hohenberg H, lzle E, et al. The outermost stratum corneum layer is an effective barrier against dermal uptake of topically applied micronized titanium dioxide. Int J Cosmet Sci 1999; 21(6): 399-411.
29. Lademann J, Weigmann H, Rickmeyer C, et al. Penetration of titanium dioxide microparticles in a sunscreen formulation into the horny layer and the follicular orifice. Skin Pharmacol Appl Skin Physiol 1999; 12(5): 247-256.
30. Puccetti G, Leblanc RM. A sunscreen-tanning compromise: 3D visualization of the actions of titanium dioxide particles and dihydroxyacetone on human epiderm. Photochem Photobiol 2000; 71(4): 426-430.
31. Bennat C, Muller-Goymann CC. Skin penetration and stabilization of formulations containing microfine titanium dioxide as physical UV filter. Int J Cosmet Sci 2000; 22(4): 271-283.
32. Schulz J, Hohenberg H, Pflucker F, et al. Distribution of sunscreens on skin. Adv Drug Deliv Rev 2002; 54(suppl 1):S157-S163.
33. Menzel F, Reinert T, Vogt J, et al. Investigations of percutaneous uptake of ultrafine TiO2 particles at the high energy ion nanoprobe LIPSION. Nucl Instrum Methods Phys Res B 2004; 219-220:82-86.
34. Lansdown AB. Interspecies variations in response to topical application of selected zinc compounds. Food Chem Toxicol 1991; 29(1): 57-64.
35. Hallmans G, Lasek J. The effect of topical zinc absorption from wounds on growth and the wound healing process in zinc-deficient rats. Scand J Plast Reconstr Surg 1985; 19(2): 119-125.
36. Agren MS. Percutaneous absorption of zinc from zinc oxide applied topically to intact skin in man. Dermatologica 1990; 180(1): 36-39.
37. Agren MS, Krusell M, Franzen L. Release and absorption of zinc from zinc oxide and zinc sulfate in open wounds. Acta Derm Venereol 1991; 71(4): 330-333.
38. Agren MS. Influence of two vehicles for zinc oxide on zinc absorption through intact skin and wounds. Acta Derm Venereol 1991; 71(2): 153-156.
39. Derry JE, McLean WM, Freeman JB. A study of the percutaneous absorption from topically applied zinc oxide ointment. JPEN J Parenter Enteral Nutr 1983; 7(2): 131-135.
40. Schwartz JR, Marsh RG, Draelos ZD. Zinc and skin health: overview of physiology and pharmacology. Dermatol Surg 2005; 31(7 pt 2): 837-847.
41. Gamer AO, Leibold E, Van Ravenzwaay B. The in vitro absorption of microfine zinc oxide and titanium dioxide through porcine skin. Toxicol In Vitro 2006; 20(3): 301-307.
42. Casey PS, Chau N, Finnin B. Issues relating to the use of Micro and nanoparticle zinc oxide in personal care products based on skin penetration studies. NSTI Nanotech Technical Proceedings, 2006, 1:541-544.
43. Cross SE, Innes B, Roberts MS, et al. Human skin penetration of sunscreen nanoparticles: invitro assessment of a novel micronized zinc oxide formulation. Skin Pharmacol Physiol 2007; 20(3): 148-154.
44. Evolution of Sunscreen Chemicals. New York, United States: Felton Worldwide, 1990.
45. Tuchinda C, Lim HW, Osterwalder U, et al. Novel emerging sunscreen technologies. Dermatol Clin 2006; 24(1): 105-117.
46. Gonzalez H, Farbrot A, Larkö O. Percutaneous absorption of the sunscreen benzophenone-3 after repeated whole-body applications, with and without ultraviolet irradiation. Br J Dermatol 2006; 154(2): 337-340.
47. Janjua NR, Kongshoj B, Andersson AM, et al. Sunscreens in human plasma and urine after repeated whole-body topical application. J Euro Acad Dermatol Venereol 2008; 22(4): 456-461.
48. Okereke CS, Abdel-Rhaman MS, Friedman MA. Disposition of benzophenone-3 after dermal administration in male rats. Toxicol Lett 1994; 73(2): 113-122.
49. el Dareer SM, Kalin JR, Tillery KF, et al. Disposition of 2-hydroxy-4-methoxybenzophenone in rats dosed orally, intravenously, or topically. J Toxicol Environ Health 1986; 19(4): 491-502.
50. Okereke CS, Kadry AM, Abdel-Rahman MS, et al. Metabolism of benzophenone-3 in rats. Drug Metab Dispos 1993; 21(5): 788-791.
51. Kadry AM, Okereke CS, Abdel-Rahman MS, et al. Pharmacokinetics of benzophenone-3 after oral exposure in male rats. J Appl Toxicol 1995; 15(2): 97-102.
52. Okereke CS, Barat SA, Abdel-Rahman MS. Safety evaluation of benzophenone-3 after dermal administration in rats. Toxicol Lett 1995; 80(1-3): 61-67.
53. Benson HA. Assessment and clinical implications of absorption of sunscreens across skin. Am J Clin Dermatol 2000; 1(4): 217-224.
54. Rastogi SC. UV filters in sunscreen products-a survey. Contact Dermatitis 2002; 46(6): 348-351.
55. Klammer H, Schlecht C, Wuttke W, et al. Multi-organic risk assessment of estrogenic properties of octyl-methoxycinnamate in vivo: a 5-day sub-acute pharmacodynamic study with ovariectomized rats. Toxicology 2005; 215(1-2): 90-96.
56. Wuttke D, Christoffel J, Rimoldi G, et al. Comparison of effects of estradiol with those of octylmethoxycinnamate and 4-methylbenzylidene camphor on fat tissue, lipids and pituitary hormones. Toxicol Appl Pharmacol 2006; 214(1): 1-7.
57. Wuttke D, Jarry H, Christoffel J, et al. Comparison of effects of estradiol (E2) with those of octylmethoxycinnamate (OMC) and 4-methylbenzylidene camphor (4MBC)-2 filters of UV light-on several uterine, vaginal and bone parameters. Toxicol Appl Pharmacol 2006; 210(3): 246-254.
58. Szwarcfarb B, Carbone S, Reynoso R, et al. Octyl-methoxycinnamate (OMC), an ultraviolet (UV) filter, alters LHRH and amino acid neurotransmitters release from hypothalamus of immature rats. Exp Clin Endocrinol Diabetes 2008; 116(2): 94-98.
59. Schneider S, Deckardt K, Hellwig J, et al. Octyl methoxycinnamate: two generation reproduction toxicity in Wistar rats by dietary administration. Food Chem Toxicol 2005; 43(7): 1083-1092.
60. Greim H. Chemicals with endocrine-disrupting potential: a threat to human health? Angew Chem Int Ed Engl 2005; 44(35): 5568-5574.